Investors in Iot

Bridford Group operates as an investment firm, focusing on identifying and investing in opportunities across various sectors. The firm provides strategic capital and operational support to companies at different stages of growth, aiming to enhance their market position and drive sustainable value creation. Bridford Group partners with management teams and entrepreneurs to leverage their industry expertise and network, fostering innovation and facilitating business expansion. By deploying flexible investment strategies, Bridford Group aims to capitalize on emerging opportunities and deliver attractive returns for its investors.

The First Thirty focuses on supporting early-stage technology companies that accelerate the regeneration of nature and the decarbonization of the fossil food system. The firm identifies and invests in startups with innovative solutions aimed at addressing environmental challenges, enhancing sustainability, and promoting eco-friendly practices in the food industry. By providing strategic capital and support, The First Thirty aims to empower entrepreneurs to drive positive environmental impact while fostering innovation and sustainable development in the global economy.

Medicxi is a leading investment firm specializing in the life sciences sector. They are dedicated to supporting innovation and advancement in biotechnology, pharmaceuticals, and healthcare. Medicxi collaborates with pioneering entrepreneurs and talented management teams to accelerate the development of breakthrough therapies, medical technologies, and healthcare solutions. With a strategic focus on early and late-stage investments, Medicxi aims to address significant medical challenges and improve patient outcomes globally. Their team combines deep scientific and investment expertise to identify promising opportunities and provide critical support throughout the growth phases of portfolio companies.

BVP is a venture capital fund manager that invests in innovative start-up companies that provide solutions for complex societal challenges related to sustainability and health. "We believe that start-ups have a crucial role to play in future-proofing the chemical, agricultural and healthcare industries." "Our mission is to support such start-ups by providing them with access to growth capital, our deep sector expertise, and decades of investment experience, as well as our vast network." "We were an impact investor well before impact investing became a buzzword. It is in our DNA." "BVP manages four funds with € 120 million committed capital:" "Limburg Ventures is a € 15 million fund that was founded in 2004." "We are a high-conviction investor. We invest in a limited number of companies in which we have a strong belief." "Actively support our portfolio companies by adding strategic value leveraging our deep sector expertise and vast investing experience."

Monograph Capital is a venture firm focused on life sciences. With a dedicated emphasis on the life sciences sector, Monograph Capital invests in innovative companies and technologies that aim to advance healthcare and biotechnology. The firm supports early-stage ventures as well as growth-stage companies, providing critical capital, strategic guidance, and industry expertise to drive their development and success. Monograph Capital's investments span across biotech, pharmaceuticals, medical devices, and other areas within the life sciences field, aiming to contribute to breakthrough discoveries, therapies, and medical advancements. Through its strategic investments, Monograph Capital plays a crucial role in accelerating innovation and improving health outcomes globally.

4BIO Capital is a specialized fund dedicated to investing in and developing early-stage advanced therapy companies. With a strategic focus on the healthcare sector, particularly in advanced therapies, 4BIO Capital supports innovative companies that are pioneering breakthrough treatments and technologies. By providing capital, strategic guidance, and industry expertise, 4BIO Capital aims to accelerate the development and commercialization of transformative therapies, contributing to advancements in healthcare and improving patient outcomes globally.

Break Off Capital is a unique investment firm dedicated to directing human and financial resources towards advancing emerging technologies that address significant global challenges. Their focus is on supporting innovations that improve quality of life today and contribute to future generations' progress. Break Off Capital aims to foster technological advancements that have the potential to make a meaningful impact on society and drive positive change worldwide.

The objective of the Ir. GJ Smid Fund is to support innovative developments in the industrial and craft fields, in order to promote and improve business activities and employment in the Northern Netherlands region, as well as to perform all activities related to the above or that may be conducive to this in the broadest sense.

INKEF Capital, established in 2010 and headquartered in Amsterdam, is a leading venture capital firm specializing in early-stage investments across Europe and the United States. The firm focuses on sectors such as life sciences, health technology, digital technology (including SaaS and AI), and industrial technology. INKEF Capital plays a pivotal role in supporting innovative companies with disruptive technologies and scalable business models, typically investing in Seed and Series A rounds, and occasionally in Series B. Beyond financial backing, INKEF Capital provides strategic guidance and operational support to its portfolio companies, leveraging a broad network of industry experts and advisors. This approach aims to accelerate growth, enhance market leadership, and navigate the complexities of scaling businesses in competitive global markets. With a diverse portfolio of promising startups and growth-stage enterprises, INKEF Capital continues to drive innovation and foster the next generation of industry leaders.

Rubio Impact Ventures is a dedicated venture capital firm focused on impact investing, specializing in early-stage companies that prioritize generating positive social and environmental outcomes alongside financial returns. Founded with a strong commitment to sustainability, Rubio Impact Ventures targets sectors critical to addressing global challenges such as clean energy, circular economy, sustainable agriculture, and technology for social good. They provide capital and strategic support to entrepreneurs developing scalable solutions that can significantly impact their industries and communities. With a global perspective, Rubio Impact Ventures leverages its sector expertise to foster innovation and drive meaningful change, aiming to build a portfolio of companies that contribute to a more sustainable and inclusive future. Through hands-on guidance and collaboration among their investments, Rubio Impact Ventures aims to maximize the collective impact of their portfolio companies while delivering sustainable financial performance.

The Dementia Discovery Fund is the largest family of specialized venture capital funds dedicated exclusively to investing in companies developing novel therapeutics for dementia. Focused on addressing the urgent need for effective treatments, the fund supports innovative startups and ventures pioneering new approaches in dementia research and therapeutics. By providing strategic investment and industry expertise, the Dementia Discovery Fund aims to accelerate the development of groundbreaking therapies that have the potential to significantly impact patients' lives worldwide.

Vlasroot is an informal investor group targeting SMEs with growth potential, proven track records, and strong management teams. They specialize in companies solving tangible problems, leveraging their extensive business and investment expertise to foster growth and help achieve strategic milestones through co-creation and network support.